Phase II study of neoadjuvant FOLFIRINOX or nab-paclitaxel with gemcitabine for borderline resectable pancreatic cancer

Phase II study of neoadjuvant FOLFIRINOX or nab-paclitaxel with gemcitabine for borderline resectable pancreatic cancer - Phase II study of neoadjuvant FOLFIRINOX or nab-paclitaxel with gemcitabine for borderline resectable pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017718

Enrollment

Registered

2015-07-01

Start date

2015-05-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

neoadjuvant chemotherapy (FOLFIRINOX) neoadjuvant chemotherapy (Nab-paclitaxel + gemcitabine)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Borderline resectable pancreatic cancer (based on NCCN guideline version 2.2015), first treatment for pancreatic cancer, performance status 0 or 1, adequate one marrow function, adequate renal function, obtained informed consent

Exclusion criteria

Exclusion criteria: Other active concomitant malignancies; other severe medical conditions; contraindication of FOLFIRINOX, paclitaxel and gemcitabine; pregnant women; no informed consent

Design outcomes

Primary

Measure	Time frame
R0 resection rate	—

Secondary

Measure	Time frame
Completion rate of chemotherapy, Relative Dose Intensity (DOI), Frequency and severity of adverse event, efficacy of chemotherapy, disease free survival, overall survival and complication of surgery	—

Countries

Japan

Contacts

Public ContactJunpei Yamaguchi

Nagoya University Graduate School of Medicine Department of Surgical Oncology

jumpei@med.nagoya-u.ac.jp052-744-2222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026